Back to the future: identification and classification of polymyalgia rheumatica and polymyalgia rheumatica-like syndromes following cancer immunotherapy with checkpoint inhibitors
Polymyalgia rheumatica (PMR) and PMR-like syndromes are among the most frequent rheumatologic immuno-related adverse events (IRAEs) induced by cancer immunotherapy with “checkpoint inhibitors” (ICIs). Our short communication addresses two key methodological issues laid bare by published literature :...
Guardado en:
Autores principales: | Ciro Manzo, Marco Isetta |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Termedia Publishing House
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/0f269c23c9a44c99b20348f186bd961d |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Polymyalgia rheumatica and cancer risk: the importance of the diagnostic set
por: Manzo C, et al.
Publicado: (2016) -
Polymyalgia rheumatica following infective triggersor vaccinations: a different subset of disease?
por: Paolo Falsetti, et al.
Publicado: (2020) -
Polymyalgia rheumatica: observations of disease evolution without corticosteroid treatment
por: Brawer AE
Publicado: (2016) -
Depression and depressive symptoms in patients with polymyalgia rheumatica: discussion points, grey areas and unmet needs emerging from a systematic review of published literature
por: Ciro Manzo, et al.
Publicado: (2020) -
Polymyalgia rheumatica with normal inflammatory indices at the time of diagnosis: can we just move a step forward?
por: Ciro Manzo, et al.
Publicado: (2020)